An interventional study of Axonics External Trial System (ETS) in Urinary Urge Incontinence (UUI), Urinary Frequency (UF) and Fecal Incontinence (FI), sponsored by Axonics, Inc.. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Axonics, Inc. (part of Boston Scientific Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 135 studies in Urinary Incontinence, Urge with a site in United States — 19 open to participants now, 26 under way, none of them phase 3. Urinary Incontinence, Urge · United States.
Among the 135 studies in Urinary Incontinence, Urge with a site in United States, this one is the 60th largest by planned enrollment of the 119 interventional ones that give a count, is one of 5 that started in 2026, is one of 72 with no phase, reaches primary completion later than 11 of the 25 other live ones, and was the 132nd registered.
243 studies on the registry are indexed under Urinary Incontinence, Urge; 39 are open to participants now.
Browse Urinary Incontinence, Urge studies →19 of the 135 studies in Urinary Incontinence, Urge with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18–89
Neuspera Medical, Inc. · Sites in United States
Ages 22+
MedtronicNeuro · Sites in United States
Ages 18+
InMode MD Ltd. · Sites in United States
Ages 22–80 · Women only
Neuspera Medical, Inc. · Sites in United States
Ages 22+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Urinary Incontinence, Urge studies recruiting now, 18 (72%) set no upper age limit and 2 (8%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
135 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 14 · Phase 4 19
First in 2003; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is below the median of 86 across 191 interventional studies indexed under Urinary Incontinence, Urge.
Median enrollment 75 across the 119 interventional studies, 47 across the 15 observational. Of the 97 that completed or were terminated, 51 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 135 have an industry lead sponsor. The 10 most frequent:
This study is registered under Axonics, Inc., one of the names counted as Boston Scientific Corporation. Under that name alone:
Axonics, Inc. is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Boston Scientific Corporation has 6 studies filed under Urinary Incontinence, Urge — fewer than ten, so there is no comparison to draw.
11 of the studies in Urinary Incontinence, Urge with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06797245Medstar Health Research InstituteAPPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women | 2026-11 |
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT07335484Axonics, Inc.Aquarius Pilot Study to Evaluate the New Axonics Trial System | 2026-11 |
| NCT07247136Neuspera Medical, Inc.Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System | 2026-11 |
| NCT06186765Axonics, Inc.F15 Recharge Free Axonics SNM System Clinical Study | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 135 studies in Urinary Incontinence, Urge with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluation of the new Axonics External Trial System (ETS-02) in patients with overactive bladder (OAB) and/or fecal incontinence (FI).
The trial system is used to determine if patients are responsive to sacral neuromodulation (SNM) prior to receiving the Axonics implantable neurostimulator (INS) which is approved for the treatment of OAB and FI. This study is evaluating the feasibility and safety of the new Axonics External Trial System (ETS-02) in patients with overactive bladder (OAB) and/or fecal incontinence (FI).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
External trial system used evaluated whether patients with OAB or FI will be responsive to sacral neuromodulation.
Device: Axonics External Trial System (ETS)
A temporary electrode wire is passed through the S3 foramen with or without fluoroscopic guidance. The wire is then connected to an external pulse generator (EPG) and is worn for a trial period ranging from 3-7 days.
Also known as: Basic or Advanced Trial
Overall Feasibility
Trial system success rate, defined as the proportion of participants with the Axonics ETS still attached and operable end of the trial period.
Time frame: Day 5-7
Adverse Events reporting (Safety)
Device- or procedure-related adverse events as determined by the independent physician adjudicated (IPA).
Time frame: Day 0-7
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.
Of 77 interventional studies with no phase under Urinary Incontinence, Urge, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 7 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.